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Cathelicidin Antimicrobial Peptide LL-37 in
Psoriasis Enables Keratinocyte Reactivity against
TLR9 Ligands
Shin Morizane1,2, Kenshi Yamasaki1,3, Beda Mu¨hleisen1, Paul F. Kotol1, Masamoto Murakami4,
Yumi Aoyama2, Keiji Iwatsuki2, Tissa Hata1 and Richard L. Gallo1
Here we show that keratinocytes in psoriatic lesional skin express increased Toll-like receptor (TLR) 9 that
similarly localizes with elevated expression of the cathelicidin antimicrobial peptide LL-37. In culture, normal
human keratinocytes exposed to LL-37 increased TLR9 expression. Furthermore, when keratinocytes were
exposed to LL-37 and subsequently treated with TLR9 ligands, such as CpG or genomic DNA, they greatly
increased production of type I IFNs. This response mimicked observations in the epidermis of psoriatic lesional
skin as keratinocytes in psoriatic lesions produce greater amounts of IFN-b than normal skin lacking LL-37.
The mechanism for induction of type I IFNs in keratinocytes was dependent on TLR9 expression but not on a
DNA–LL-37 complex. These findings suggest that keratinocytes recognize and respond to DNA and can actively
participate in contributing to the immunological environment that characterizes psoriasis.
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INTRODUCTION
Keratinocytes are a well-described source of inflammatory
mediators that influence T-cell and other leukocyte functions.
However, it remains unclear how the production of a variety of
cytokines and chemokines by keratinocytes influences the
development of inflammatory skin diseases. For example,
although the pathogenesis of psoriasis is incompletely under-
stood, altered T-cell-mediated immune responses are thought
to be critical to manifestations of the disease. Although it is
clear that T-cell function is a major determinant of the local
inflammatory events that lead to the characteristic manifesta-
tions of psoriasis, recent studies of skin immune defense
systems have highlighted the importance of innate immunity, a
primary responsibility of epithelial cells and granulocytes. This
study sought to better define the potential role of the innate
immune system of keratinocytes in triggering inflammation.
Keratinocytes following injury, or in psoriatic lesional skin,
are characterized by the excessive production of antimicrobial
peptides (AMPs) such as b-defensins and cathelicidin (Gallo
et al., 1994; Harder et al., 1997; Liu et al., 1998; Dorschner
et al., 2001; Ong et al., 2002). These antimicrobial molecules
are known for integral roles of killing pathogenic microorgan-
isms, but AMPs also modify host inflammatory responses by a
variety of mechanisms (Lai and Gallo, 2009). The cathelicidin
peptide LL-37 has been described as enabling plasmacytoid
dendritic cells (pDCs) to recognize self-DNA through Toll-like
receptor (TLR) 9 (Lande et al., 2007). The importance of this
stimulation of dendritic cell gains relevance to psoriasis in the
context of the capacity of these dendritic cells to influence
T-cell polarization critical to manifestation of the disease, and
include inflammatory cytokines such as type I IFNs, IL-17A,
IL-22, and IL-23 (Nestle et al., 2009). The significance of Th17
cytokines to psoriasis has been confirmed by observations of
the efficacy of therapeutic approaches directed to neutral-
ization of the Th17 axis (Di Cesare et al., 2009). Thus,
keratinocytes and neutrophils, through the release of LL-37,
may provide a critical cofactor for the recognition of self-DNA
by dendritic cells, and this in turn can be a critical element in
the pathophysiology of the disease.
As keratinocytes produce and are directly exposed to
AMPs in psoriatic skin, are the most numerous cell type
present in psoriatic lesions, and also have the capacity to
influence T-cell polarization through production of type I
IFNs and other cytokines (Ong et al., 2002; Lebre et al.,
2007), we investigated here whether epidermal keratinocytes
might also be responsive to self-DNA and contribute to the
production of cytokines critical to the development of
& 2012 The Society for Investigative Dermatology www.jidonline.org 135
ORIGINAL ARTICLE
Received 12 January 2011; revised 21 June 2011; accepted 25 June 2011;
published online 18 August 2011
1Division of Dermatology, Department of Medicine, University of California,
San Diego and VA San Diego Healthcare System, San Diego, California, USA;
2Department of Dermatology, Okayama University Graduate School of
Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan;
3Department of Dermatology, Tohoku University Graduate School of
Medicine, Sendai, Japan and 4Department of Dermatology, Asahikawa
Medical College, Asahikawa, Japan
Correspondence: S Morizane, Department of Dermatology, Okayama
University Graduate School of Medicine, Dentistry, and Pharmaceutical
Sciences, 2-5-1, Shikata-cho, Okayama 700-8558, Japan.
E-mail: zanemori@cc.okayama-u.ac.jp
Abbreviations: AMP, antimicrobial peptides; PBS, phosphate-buffered saline;
pDC, plasmacytoid dendritic cell; SELDI-TOF-MS, surface-enhanced laser
desorption/ionization time-of-flight mass spectrometry; TLR, Toll-like receptor
psoriasis and inflammation. We show here for the first time
that keratinocytes recognize and respond to DNA and can
actively participate in contributing to the immunological
environment that characterizes psoriasis.
RESULTS
Increased LL-37 is associated with elevated TLR9 in psoriatic
epidermis
We hypothesized that the expression and function of TLRs by
epidermal keratinocytes might be a critical element in
amplifying the immune response. Measurement of TLR
mRNA abundance in skin biopsies of psoriatic lesion
revealed that TLR9, but not the other TLRs, was signifi-
cantly elevated in psoriatic lesional skin compared with
psoriatic non-lesional skin or lesional skin of atopic
dermatitis (Figure 1a–d), which are consistent with a previous
report (Miller et al., 2005). TLR3 expression was significantly
decreased in lesional skin of atopic dermatitis compared
with psoriatic lesional skin. The increase of TLR9 expression
in psoriatic lesional skin corresponded with increased
TLR9 production in keratinocytes as immunohistochemical
staining revealed that TLR9 protein expression was greatly
enhanced in keratinocytes (Figure 1e–g). TLR9-positive cells
are also seen in the dermis of psoriatic lesional skin.
Co-immunostaining revealed that cathelicidin was similarly
located with TLR9 in the psoriatic epidermis (Figure 1h–j).
As immunohistochemical identification of cathelicidin in
this study and prior studies (Frohm et al., 1997) has not
defined the peptide form of cathelicidin present in psoriasis,
and these various proteolytically processed forms are critical
to the function of the peptide (Braff et al., 2005; Yamasaki
et al., 2007), we performed surface-enhanced laser desorp-
tion/ionization time-of-flight mass spectrometry (SELDI-TOF-
MS) on whole extracts of psoriatic lesional skin to define the
peptide mass and thus its sequence. Unlike normal skin or
skin from other inflammatory disorders such as rosacea
(Yamasaki et al., 2007), all cathelicidin detectable in psoriasis
was in the form of LL-37 (Figure 1k).
LL-37 induces TLR9 expression in keratinocytes
We next evaluated whether the presence of LL-37 could
influence the expression of TLR9 in keratinocytes. Cultures of
normal human epidermal keratinocytes were exposed to
LL-37 at concentrations within the physiological range of
cathelicidin previously measured in psoriatic skin (Ong
et al., 2002). Keratinocytes cultured with LL-37 increased
expression of mRNA for TLR9, but not TLR1, TLR2, or TLR3
(Figure 2a), a pattern similar to the expression of TLRs found
in psoriatic epidermis. TLR5 and TLR6 were not signifi-
cantly increased, and TLR4, TLR7, and TLR8 were not
consistently detectable in cultured keratinocytes (data not
shown). We also examined the effect on TLR9 expression of
inflammatory cytokines including IL-22, but under these
culture conditions IFN-g, IL-4, IL-17A, IL-22, or tumor
necrosis factor-a did not induce TLR9 mRNA in keratino-
cytes (Figure 2b). LL-37 induced TLR9 expression in a
dose-dependent manner (Figure 2c), and a peak increase of
TLR9 mRNA was observed 12 hours after the stimulation
(Figure 2d). TLR9 protein increase paralleled TLR9 mRNA
induction by LL-37 (Figure 2e–g).
LL-37 enhances type I IFN expression from keratinocytes
exposed to DNA
To evaluate the functional significance of keratinocyte TLR9,
IFNA2 and IFNB1 mRNA abundance was measured in the
presence of the TLR9 ligand CpG DNA. As previously
reported (Miller et al., 2005), CpG by itself had minimal
effect on keratinocytes but greatly increased type I IFNs
(IFNA2 and IFNB1 mRNA in the presence of LL-37 (Figure 3a
and b)). Whole genomic DNA had a similar effect to simulate
IFN expression in the presence of LL-37 (Figure 3c). The
induction of IFNB1 expression was dose-dependent of LL-37
(Figure 3d). A corresponding increase of IFN-b protein was
also confirmed by ELISA (Figure 3e and f) and the induction
was observed 24 hours after the stimulation (Figure 3g).
This effect was significantly inhibited by the TLR9 antagonist
guanosine-rich oligodeoxynucleotides (Figure 3h).
Psoriatic keratinocytes express IFN-b
The in vitro experiments predicted that epidermal keratino-
cytes affected by LL-37 would produce type I IFNs. As
expected, keratinocytes in lesional skin from psoriatic
patients showed abundant expression of IFN-b compared
with keratinocytes from normal skin that had small amounts
of LL-37 (Figure 4a–c). IFN-b-positive cells were also
observed in the upper dermis (Figure 4d–f). A corresponding
increase of IFNB1 mRNA was confirmed by real-time PCR of
skin biopsies (Figure 4g).
Keratinocytes respond to sequential exposure to LL-37 and
CpG, but not to LL-37 complexed to CpG
LL-37 and DNA have been previously proposed to form a
complex between the peptide and nucleic acids to activate
TLR9 in pDCs; thus, LL-37 protects DNA from degradation
and facilitates DNA entry into the early endosome (Lande
et al., 2007). The methods used in Figure 3 relied on the
addition of LL-37 to keratinocytes, followed by sequential
addition of CpG. This approach may have enabled formation
of a complex between the cationic peptide and anionic DNA.
Alternatively, LL-37 may have directly interacted with the
keratinocyte membrane to enhance entry of CpG. To
distinguish these events, LL-37 and CpG were first mixed
together to allow complex formation. Assembly of these two
molecules into a complex was confirmed by HPLC. CpG
alone was seen as the expected single peak (Figure 5a). Once
CpG was preincubated with LL-37, the assembly into a
multimeric complex could be directly visualized by the
disappearance of the single peak of CpG and the appearance
of several broad peaks (Figure 5b). However, the CpG/LL-37
complex was not able to enhance type I IFNs production from
keratinocytes. In contrast, sequential addition of LL-37
followed immediately by CpG at the same concentrations
as used in the complex was required to stimulate keratinocyte
IFN expression (Figure 5c).
We also examined whether other cathelicidin AMPs
have similar capacity to increase IFNs production from
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Figure 1. Toll-like receptor (TLR) 9 is increased in psoriatic epidermis and similarly localizes with elevated cathelicidin processed as LL-37. (a–d) TLR mRNA
expression was analyzed and normalized with the mean of non-lesional skin from psoriasis patients. AD-L, lesional skin from atopic dermatitis patients (n¼ 7);
PS-L, lesional skin from psoriasis patients (n¼ 5); PS-N, non-lesional skin from psoriasis patients (n¼ 11). **Po0.01, ***Po0.001. (e–g) TLR9 protein
expression was examined by immunofluorescence, and 40-6-diamidino-2-phenylindole-visualized nuclei. Bar¼250 mm. (h–j) The localization of
cathelicidin (green) and TLR9 (red) in psoriatic lesional skin was visualized by immunofluorescence. Bar¼ 250mm. Data are representative of three
samples (e–j). (k) Mass of cathelicidin peptides extracted from psoriatic lesional skin was examined by surface-enhanced laser desorption/ionization
time-of-flight mass spectrometry. The arrow indicates the peak of LL-37. Data are representative of five samples.
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keratinocytes. KS-30, a derivative of LL-37, which has
previously shown the capacity to activate IL-8 expression in
keratinocytes (Braff et al., 2005), showed a similar ability to
increase type I IFN when added before CpG (Figure 5d).
Several other cationic peptides including the murine cathe-
licidin peptide mCRAMP (GL-33), other human cathelicidin
peptides such as FA-29 and DI-27, or the cationic but
unstructured proline-rich antimicrobial porcine cathelicidin
peptide PR-39 did not enhance type I IFNs induction. Although
these cationic AMPs could not enhance type I IFNs in
keratinocytes, they were still able to bind and form complexes
with CpG as observed by HPLC analysis (data not shown).
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Figure 2. LL-37 induces Toll-like receptor (TLR) 9 expression in keratinocytes. (a–d) Normal human epidermal keratinocytes were treated with LL-37
(0.1–10 mM) or cytokines for 3–48 hours, and then TLR mRNA expression was analyzed by quantitative real-time PCR. Data are mean±SEM of triplicate samples
and representative of three independent experiments. ***Po0.001. (e–g) TLR9 protein expression was examined by immunofluorescence, and nuclei were
visualized with 40-6-diamidino-2-phenylindole (DAPI). Bar¼ 100 mm.
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Overexpression of TLR9 enhances type I IFN induction by the
ligands in keratinocytes
We further investigated the role of TLR9 in keratinocyte
recognition of DNA by transient overexpression of TLR9 in
keratinocytes. Plasmid DNA encoding human TLR9 (pUNO-
hTLR9-HA) was transfected into keratinocytes. These cells
(or controls) were then exposed to CpG or LL-37, and then to
CpG. Transfection of pUNO-hTLR9 increased TLR9 mRNA
expression several fold (Figure 6a). Addition of CpG alone
increased IFNB1 approximately threefold in keratinocytes
transfected with TLR9 (pUNO-TLR9), but not the control
(pUNO-mcs; Figure 6b). As seen previously, LL-37 treatment
of control keratinocytes greatly enhanced IFNB1 expression
by the sequential stimulation with CpG (Figure 6c). This
increase occurred to a significantly larger extent when cells
were transfected with pUNO-TLR9-HA. Genomic DNA had a
similar effect in the presence of LL-37 (Figure 6d).
DISCUSSION
In the current study, we have shown for the first time that
keratinocytes will respond to DNA with a large increase in
release of type I IFNs, and that this occurs in a LL-37-
and TLR9-dependent manner. This previously unknown
phenomenon, combined with the importance of type I IFNs
in the pathogenesis of psoriasis, suggests that the abundant
keratinocytes expressing LL-37 in psoriatic lesional skin could
make a critical contribution to disease pathogenesis.
LL-37 is the carboxy-terminal peptide fragment derived
from the human cathelicidin precursor protein hCAP18. This
peptide not only has the capacity to kill a wide variety of
microbes, but also can modify host immune and growth
responses (Lai and Gallo, 2009). LL-37 has been reported to
form a complex with self-DNA and self-RNA to induce IFN-a
in pDCs through TLR9 and TLR7, and hypothesized to drive
autoimmunity in psoriasis by this peptide–nucleic acid-
binding phenomenon (Lande et al., 2007; Ganguly et al.,
2009). In the present study, we have observed that LL-37 and
the alternatively processed cathelicidin peptide KS-30 can
both greatly increase type I IFN production from keratino-
cytes, whereas other AMPs of similar cationic charge and
antimicrobial potency cannot.
The expression and processing of the cathelicidin
precursor protein is specific for the cell, tissue, and disease
state. Cathelicidin is found at low levels in normal skin and is
not in the form of LL-37 (Yamasaki et al., 2007). In contrast,
excess cathelicidin is seen in the inflammatory skin disease
rosacea, but in contrast to normal skin these cathelicidin
peptides are found in several unique forms (Yamasaki et al.,
2007). Our findings here of elevated cathelicidin in psoriasis
are consistent with previous observations in this disease
(Frohm et al., 1997; Ong et al., 2002) Furthermore, we now
show by SELDI-TOF-MS of psoriatic lesional skin that
the predominant peptide form of cathelicidin is indeed in
the form of LL-37. It was not previously known that LL-37 was
the exclusive detectable form of cathelicidin in psoriasis.
In this way, psoriasis differs significantly from rosacea where
many cathelicidin peptide forms other than LL-37 are present.
The significance of observing different processed forms of the
cathelicidin is that different peptide forms have different
antimicrobial activities and proinflammatory functions (Braff
et al., 2005). Thus, although psoriasis and rosacea both have
elevated cathelicidin expression, the balance of peptides with
different and potentially competitive actions may partially
explain differences in phenotype.
Keratinocytes in psoriatic lesional skin have previously
been shown to express TLR9, and cultured keratinocytes
express it in a weakly functional form (Miller et al., 2005; Lebre
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Figure 3. LL-37 enhances Toll-like receptor 9 responsiveness in
keratinocytes. (a–h) Normal human epidermal keratinocytes were stimulated
with LL-37 (0.1–10mM), and then CpG (2 mM), gDNA (10 mgml1),
G-ODN (4 mM), or their combinations for 24–72 hours. (a–d, h) The expression
of IFNA2 and IFNB1 mRNA was analyzed by quantitative real-time PCR.
(e–g) Protein expression of IFN-b in the media was measured by ELISA. gDNA,
genomic DNA; G-ODN, guanosine-rich oligodeoxynucleotides. *Po0.05,
**Po0.01, ***Po0.001. Data are mean±SEM of triplicate samples and
representative of three independent experiments.
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et al., 2007). The present study shows in vitro that in addition
to enhancing of the capacity of TLR9 to respond to DNA, LL-37
also induces an increase in TLR9 expression in keratinocytes.
The increase in TLR9 seen after LL-37 is not likely to be the
only reason for increased TLR9 responsiveness as increased
function was seen immediately after LL-37 addition, thus not
allowing time for increased expression of TLR9. The ability of
LL-37 to increase TLR9 expression is consistent with the
elevated abundance and similar location of cathelicidin and
TLR9 seen by immunostaining of psoriatic epidermis.
The mechanism through which TLR9 is induced by LL-37 is
unclear at present. LL-37 is known to induce IL-8 in
keratinocytes through Gi protein-coupled receptor or EGFR-
dependent signaling events (Braff et al., 2005). The Gi protein
inhibitor pertussis toxin, or EGFR tyrosine kinase inhibitor
AG1478, however, did not inhibit the increase in TLR9 by LL-
37 (Supplementary Figure S1 online), suggesting that induction
of TLR9 by LL-37 is independent of Gi protein and EGFR
signaling. Thus, further investigation is required to understand
how LL-37 enables keratinocytes to increase TLR9.
The consequence of increased type I IFN production by
keratinocytes may be that these cells become an important
and active participant in exacerbating psoriasis. Much
evidence has previously been assembled to suggest that
type I IFNs contribute to this disease (Nestle et al., 2005).
pDCs are currently thought to be major type I IFN-producing
cells, and produce large amount of IFN-a in psoriasis (Nestle
et al., 2005). A complex between LL-37 and DNA has been
previously proposed to be necessary for activation of TLR9 in
pDCs (Lande et al., 2007), and we examined whether this
mechanism is also involved in the keratinocyte TLR9 response.
We confirmed that CpG and LL-37 can form a complex. This is
not surprising as all cationic peptides tested have this
capacity to bind anionic nucleic acids. However, these
complexes did not induce type I IFNs in keratinocytes. Only
LL-37 and a unique derivative of this peptide were active, and
this occurred only when the keratinocytes were first treated
with the peptide. Therefore, in keratinocytes, it appears that
LL-37 must first interact with the cell membrane, an interaction
that is known to alter membrane fluidity (Di Nardo et al.,
2007). Presumably, this interaction enables subsequent
recognition by TLR9. It is unclear whether this membrane
permeability phenomenon also takes place in pDCs in
addition to or in lieu of the DNA binding and protection
hypothesis that has been previously put forward. Thus, unlike
that previously reported for pDCs, the present findings suggest
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that the binding of LL-37 to DNA is not the mechanism of
action to stimulate keratinocyte TLR9 activation.
Overexpression of TLR9 in keratinocytes enhances the
synergistic induction of type I IFNs, thus supporting that the
response to CpG was TLR9 dependent. LL-37 further
enhanced the response of keratinocytes transfected with a
TLR9-expressing vector. These results indicate that TLR9
expression levels alter the sensitivity to its ligands. Combined
with the results that LL-37 increased TLR9 expression in
keratinocytes, and that LL-37 and TLR9 are similarly located
and highly expressed in the epidermis of psoriasis, these
suggest that keratinocytes are poised to respond to TLR9
ligands in vivo and together may be critical to pathogenesis
of the disease. In support of this hypothesis are recent
observations that psoriatic patients who improve on etaner-
cept therapy also show a decrease in TLR9 expression but
maintain elevated levels of LL-37 in their lesional skin (Miller
et al., 2011).
In summary, we have shown that the activation of
keratinocytes by LL-37 enhances TLR9 responsiveness to
DNA and greatly increases the production of type I IFNs. The
epidermis is a rich source of genomic DNA that can be
released by trauma, infection, and normal differentiation.
Thus, the stimulus for these events and the responding cells
all exist in the epidermis. Recently, Dombrowski et al.
(2011) have reported that LL-37 also serves as an anti-
inflammatory agent by blocking activation of the DNA-
sensing inflammasomes, which might be a mechanistic
explanation why vitamin D, a strong cathelicidin inducer in
keratinocytes, is effective for psoriasis. They showed that
intracellular LL-37 blocks the DNA-triggered formation of
AIM2 inflammasomes in keratinocytes, inhibiting IL-1b
release. Because our current study demonstrated that extra-
cellular or endosomal LL-37 enhances TLR9 expression
and function in keratinocytes, leading to increased IFN-a/b
production, the location of LL-37 and DNA might be
crucial for their pro- or anti-inflammatory effect. Thus,
LL-37/DNA complex formation may be important because
it is required for the anti-IL-1b effect, but sequential
exposure leads to a pro-IFN-a/b effect in keratinocytes.
These findings therefore uncover a previously underappre-
ciated role for keratinocytes in modulating the immune
response in psoriasis and suggest that targeting these
superficial events for therapy could provide a mechanism
to improve disease without the risks of systemic immuno-
suppressive approaches.
MATERIALS AND METHODS
Skin biopsies
This study was approved by the Human Research Protection
Program at the University of California, San Diego, and performed
in accordance with the Declaration of Helsinki Principles. Skin was
collected from patients with psoriasis or atopic dermatitis and from
healthy volunteers. For all procedures, informed consent was
obtained. After the injection of local anesthesia, 2 or 4mm punch
biopsies were taken from the untreated lesional skin of individuals
with psoriasis or atopic dermatitis and from healthy volunteers.
All samples were stored at 80 1C until use.
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Peptide synthesis
Cathelicidin peptides, LL-37, GL-33, PR-39, KS-30, FA-29,
and DI-27 were commercially prepared by Synpep (Dublin,
CA) (Dorschner et al., 2001; Murakami et al., 2004; Yamasaki
et al., 2007).
Cell culture and stimuli
Normal human epidermal keratinocytes were cultured as
described previously (Morizane et al., 2010). Cells were stimulated
with synthetic cathelicidin peptides (LL-37, GL-33, PR-39,
KS-30, FA-29, DI-27, 0.1–10mM), IFN-g (2 ngml1, R&D Systems,
Minneapolis, MN), IL-4, IL-17A, IL-22 (50 ngml1, R&D Systems),
tumor necrosis factor-a (50 ngml1, Chemicon, Temecula, CA),
type C CpG oligodeoxynucleotides M362 (2mM, Invivogen,
San Diego, CA), genomic DNA (10 mgml1), or guanosine-rich
oligodeoxynucleotides (4mM, Invivogen) in 24-well flat-bottomed
plates (Corning Incorporated Life Sciences, Lowell, MA) for
3–72 hours. Genomic DNA was purified from HaCaT cells
by Wizard Genomic DNA Purification Kit (Promega, Madison,
WI). Pertussis toxin (100 ngml1, Sigma-Aldrich, St Louis, MO)
and AG1478 (2 mM, Calbiochem, San Diego, CA) were used to
preincubate for 1 hour.
Plasmid DNA transfection
Transfection was performed by Amaxa Human Keratinocytes
Nucleofector Kit (Lonza Cologne AG). Normal human epidermal
keratinocytes at 60–70% confluency were harvested by trypsiniza-
tion and 1 106 cells were transfected with 3 mg plasmid DNA,
pUNO-mcs (control plasmid), or pUNO-hTLR9-HA (Invivogen),
following the protocol. Transfected cells were incubated in six-well
plates at 37 1C under standard tissue culture conditions for 24 hours.
The cells were then stimulated with CpG or LL-37, and then with
CpG or genomic DNA for 24 hours.
Quantitative real-time PCR
Total RNA from skin samples and cultured keratinocytes was
extracted, and cDNA was synthesized as previously written
(Buchau et al., 2009). TaqMan Gene Expression Assays (Applied
Biosystems ABI, Foster City, CA) were used to analyze mRNA
expression as described by the manufacturer. Glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) and 18S ribosomal RNA
were examined as previously written (Taylor et al., 2007; Morizane
et al., 2010). mRNA expression was calculated as relative expres-
sion to GAPDH mRNA (cultured cell samples) or 18S ribosomal
RNA (skin samples), and data are presented as fold change against
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Figure 6. Overexpression of Toll-like receptor (TLR) 9 enhances IFN-b production by the ligands in keratinocytes. (a) Normal human epidermal keratinocytes
were transfected with pUNO-mcs or pUNO-hTLR9-HA using Amaxa Human Keratinocyte Nucleofector Kit. After 24 hours transfection, TLR9 mRNA
expression was examined. (b–d) After 24 hours transfection with pUNO-mcs or pUNO-hTLR9-HA, NHEKs were stimulated with CpG alone (2 mM) (b) or LL-37
(10mM), and then CpG (2 mM) (c) or genomic DNA (gDNA) (10mgml1) (d) for 24 hours. The expression of IFNB1 mRNA was analyzed by quantitative real-time
PCR. *Po0.05, **Po0.01. Data are mean±SEM of triplicate samples and representative of two independent experiments.
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each control (mean of non-stimulated cells or mean of psoriatic
non-lesional skins).
ELISA
IFN-b in culture media was measured by a commercial sandwich
ELISA, following the manufacturer’s instructions (PBL Interferon-
Source, Piscataway, NJ).
Immunostaining
For immunohistofluorescence, frozen sections (6mm) were fixed with
4% paraformaldehyde, blocked with 3% BSA in phosphate-buffered
saline (PBS), and incubated with mouse monoclonal anti-TLR9
antibody (IMGENEX, San Diego, CA), rabbit anti-LL-37 antibody, or
mouse monoclonal anti-IFN-b antibody at 4 1C overnight. Normal
mouse and rabbit IgG were used as negative control. After washing
with PBS, FITC-conjugated goat anti-mouse IgG antibody (Sigma-
Aldrich) for TLR9 or IFN-b staining or FITC-conjugated goat anti-
rabbit IgG antibody (Jackson Immuno Research Laboratories, West
Grove, PA) and AlexaFluor568-conjugated goat anti-mouse IgG
antibody (Molecular Probes/Invitrogen) for double staining of TLR9
and LL-37 were used as second antibody. For immunocytofluores-
cence, keratinocytes were grown on chamber slides. After 4%
paraformaldehyde fixation and blocking with 3% BSA in PBS, TLR9
staining was performed as described above. Sections were mounted
in ProLong Gold Anti-Fade reagent with 40-6-diamidino-2-phenylin-
dole (Molecular Probes/Invitrogen, Eugene, OR). Images were
obtained using an Olympus BX41 fluorescent microscope (Scientific
Instrument Company, Temecula, CA).
Surface-enhanced laser desorption/ionization time-of-flight
mass spectrometry
Cathelicidin peptides were analyzed by SELDI-TOF-MS as pre-
viously written (Yamasaki et al., 2007).
Size-exclusion HPLC
Superdex75 Columns (Amersham Biosciences, Piscataway, NJ) and
AKTA purifier HPLC system (Amersham Biosciences) were used for
analysis. CpG (500pmol) was preincubated with LL-37, GL-33, or PR-39
(2.5nmol) in 100ml PBS overnight. The samples were eluted with PBS at
a flow rate of 1.0mlmin1. The detection wavelength was 214nm.
Statistics
Results are expressed as the mean±SEM. Student’s t-test was used to
determine significance. Mann–Whitney U-test was used to compare
IFN-b protein expression and mRNA expression in skin samples
between each group. Po0.05 was considered significant.
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